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EgyptAbstract Introduction
Lymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ALL) are neoplasms of imma-
ture B or T-cell precursors. They are considered as a unique biological entity in the 2008 World
Health Organization Classification of Hematologic Neoplasm. Both entities are arbitrarily sepa-
rated by a cut-off point of 20–25% of blast cells in the bone marrow. Treatment of LBL has evolved
over time from conventional high-grade NHL schedules to ALL-derived protocols.
The aim of this work is to report the clinical characteristics, overall survival (OS), event free survival
(EFS), and common chemotherapy toxicities of lymphoblastic lymphoma (LBL) patients during a
5.5 year period.
Patients and methods
A Retrospective review of patient’s charts diagnosed and treated as LBL during the period between
July 2007 and end of December 2012 was done. Patients were treated according to St. Jude Children
Research Hospital ALL Total Therapy XV protocol, standard risk arm.
Results
This study included 77 patients. T-cell LBL patients were 67, while 10 were of B-cell origin. The
median age at diagnosis was 9 years (95% CI: 7–10). The majority were males 54/77. Stage III
patients were 51, stage IV 13, stage II 11 and stage I 2 patients. Two patients were excluded from
analysis as they died before receiving chemotherapy. Complete remission post induction
176 H.A. Rahman Sayed et al.chemotherapy was seen in 22 patients considered early responders, and partial remission in 55 con-
sidered late responders. With a median follow up duration of 47 months (95% CI: 38–56), the
4 year overall survival and event free survival were 86.45% (95% CI: 73.78–94.09) and 82.18%
(95% CI: 69.25–90.61) respectively.
Twelve patients died during the study period; 2 early deaths before starting chemotherapy from dis-
ease progression, 2 in CR due to chemotherapy related toxicity and 8 from disease progression. All
the relapsed patients were T-cell, had advanced disease at presentation (6 with stage III; 2 with stage
IV). Two patients (2.6%) had isolated local, BM, and CNS relapse each, while 1 (1.3%) had both
local and CNS relapse. Disease recurrence was local in 3 patients (3.9%), and systemic in 5 (6.4%),
while it was early in 6 (7.8%), and late in 2 (2.6%) patients. Median time to disease progression was
20 months (range 5–39 months). All relapsed patients did not survive salvage chemotherapy. The
most common chemotherapy toxicities were cerebral venous thrombosis (20%), followed by bone
infarcts (10.6%), and avascular necrosis (AVN) of head of femur (9.3%). One patient developed
secondary acute myeloid leukemia after 3 years of FU with unfavorable cytogenetic abnormalities.
Conclusion
Results of treatment of LBL on the St Jude’s total therapy XV study are comparable to most of the
similar reported studies. Outcome of relapsing patients is extremely poor, hence there is a need to
identify biologic or clinical prognostic factors including minimal residual tumor to better evaluate
chemotherapy response. Steroid induced AVN, and cerebral vascular thrombosis were the main
chemotherapeutic adverse events.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
NHL is a diverse collection of malignant neoplasm derived
from mature and immature lymphoid cells of either B-cell or
T-cell origin [1]. Lymphoblastic Lymphoma (LBL) has been
used to describe predominantly lymph node–based disease. It
accounts for 30% of pediatric NHL [2]. The current WHO
classification, recognized that this entity represents a spectrum
of precursor lymphoid cell disease and developed the diagnos-
tic category of lymphoblastic leukemia/lymphoma [3]. Both
diseases share common characteristics, such as immunopheno-
typic (IPT) features, lymphoblast morphology and clinical
characteristics, e.g. the median age at diagnosis, and the favor-
able outcome after ALL-type chemotherapy [4–6]. For a low
stage disease, survival rate is >90%, while for an advanced
stage disease survival is >80% [4]. Nevertheless, small molec-
ular profiling studies and genomic studies have demonstrated
differential gene expression profiles and loss of heterozygosity
at the 6q locus, suggesting the presence of underlying biologic
differences [7,8]. T-cell LBL versus T-ALL has less hep-
atosplenomegaly, central nervous system involvement, better
survival and heterogeneity in IPT reflecting various stages of
T-cell development [9]. Moreover, the typical sites of relapse
differ, with predominantly local in LBL [4,10], and systemic
relapse in ALL. The time to relapse tends to be minimally
shorter in LBL than in ALL [9].
The aim of this work is to report the clinical characteristics,
overall survival (OS), event free survival (EFS), and common
chemotherapy toxicities of LBL patients treated at the Chil-
dren Cancer Hospital Egypt during a 5.5 year period.Patients and methods
This retrospective study was carried out at the Children
Cancer Hospital Egypt. Data of treated patients during theperiod from July 2007 to end of December 2012 were collected
from the medical record department.
Patients were included in the study if they were newly diag-
nosed with LBL by pathology, immunophenotyping (IPT),
and cytochemistry, were equal to or less than 18 years of
age, and had no other co-morbidities and/or immunodefi-
ciency syndromes. Written informed consent and institutional
review board (IRB) approval were obtained before starting the
study.
The following data were collected from patient’s files:
1. Epidemiologic data regarding age, gender, and clinical
presentation.
2. Laboratory and radiological initial work up: blood count,
serum electrolytes, bone marrow (BM) aspirate, cere-
brospinal fluid analysis (CSF), and imaging studies includ-
ing computed tomography (CT scan).
3. Staging according to the St Jude staging system [11].
4. Assessment of response at time of evaluation as required by
the applied protocol (end of induction, week 7, 17, 48, and
end of chemotherapy).
5. Major organ toxicities [12].
6. Causes of death during chemotherapy and FU period.
7. OS and EFS of the studied patients.
Chemotherapy: patients included in this study were treated
according to ALL Total Therapy Study XV at St. Jude Chil-
dren’s Research Hospital, standard risk arm. Treatment
included the following phases:
Remission induction (6 weeks): prednisone (40 mg/m2 
28 days), vincristine (1.5 mg/m2 max 2 mg days 1,8,15,22),
daunorubicin (30 mg/m2 days 1, 8), asparginase (25,000 IU/
m2days 1,5,9,11,13), and weekly triple intrathecal treatment
(age adjusted), cyclophosphamide (1000 mg/m2 day 2), cytara-
bine (75 mg/m2 days 23–26, and 32–35) and 6 mercaptopurine
(60 mg/m2 days 23–36).
Table 1 Characteristics of the 77 studied patients.
No. of
patients
Percentage
(95% CI)
Sex
Male 54 70.13 (58.62–80.03)
Female 23 29.87 (19.97–41.38)
Age (years)
Range 1–17
Median 9 (7–10)
Immunophenotyping
T-LBL 67 87.01 (77.41–93.59)
B-LBL 10 12.99 (6.41–22.59)
Clinical presentation
Mediastinal mass 40 51.9 (40.26–63.48)
RD 26 33.7 (23.38–45.45)
Generalized lymphadenopathy 22 28.5 (18.85–40)
Cervical lymph node 5 6.4 (2.14–14.51)
Stage
I 2
II 11 14.3 (7.35–24.13)
III 51 66.2 (54.55–76.62)
IV 13 16.8 (9.31–27.14)
BM infiltration 11 14.3 (7.35–24.13)
CNS involvement 2
Response at end of induction
(n= 75)
CR 20 26.67 (17.11–38.14)
PR 55 73.33 (61.86–82.89)
BM: bone marrow, CNS: central nervous system, CR: complete
remission, LBL: lymphoblastic lymphoma, PR: partial remission,
RD: respiratory distress.
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5gm/m2 (every two weeks for 4 doses), associated with triple
intrathecal and daily 6 mercaptopurine (50 mg/m2).
Continuation/maintenance treatment (24 months): started
two weeks from the start of the last high does Methotrexate:
– Monthly vincristine 2 mg/m2 (maximum dose 2 mg) IV
push.
– Dexamethasone 12 mg/m2/day PO divided TID x 5 days,
every 28 days.
– 6 mercaptopurine 50 mg/m2/day till week 20, then 75 mg/
m2/day, PO, once a day.
– Methotrexate 40 mg/m2/day IM weekly.
– Doxorubicin 30 mg/m2/day 1 IV over 4 h infusion on week
1, 4, 7, 8, 11, 14.
– Asparginase 25,000 IU/m2/day 1 IM week 1–19.
– Cyclophosphamide and Ara-C 300 mg/m2 each, iv monthly
for 12 doses.
Patients were given continuous treatment for two years.
Assessment of tumor response was done at the scheduled time.
In case of inadequate response; patients continued the same
line of chemotherapy till documented evidence of disease
progression.
Definitions and criteria of response:
Complete Response (CR): complete disappearance of all
clinical evidence of disease by physical examination, imaging
studies, BM aspirate, and/or CSF evaluation (when indicated).
Early Responders: Those patients achieving CR after induc-
tion treatment.
Partial Response (PR): a decrease of 30% or more in the
nodal masses, but not satisfying the criteria for CR.
Late Responders: Those patients achieving PR after induc-
tion treatment.
Relapse (RL): appearance or reappearance of tumor in any
site.
Progressive Disease (PD): an increase of >25% or the
reappearance of tumor in any site of residual disease compared
to immediate pre-study volume or best prior response at that
site.
Early relapse: recurrence within 36 months from initial
diagnosis.
Late relapse: recurrenceP36 months from initial diagnosis,
or >6 months after the completion of chemotherapy.
Statistical analysis
The potential follow-up time for each patient was the time
from enrollment to the closing date for analyses or the date
of last information. For OS, all deaths were counted regardless
of cause, and survival times for living patients were censored
on the closing date. For EFS, the first progression at any site
or death without progression was counted as an event, and
times were censored on the date for the patient, who was alive
on the date without disease progression.
Data were analyzed using IBM SPSS advanced statistical
version 20 (SPSS Inc., Chicago, IT). Numerical data were
expressed as mean and standard deviation or median and
range as appropriate. Qualitative data were expressed as fre-
quency and percentage. Owing to our small sample size, the95% confidence intervals for all the results were calculated
by binomial exact method [13].
Survival analysis (OS and EFS) was done using Kaplan–
Meier method and the comparison between two survival
curves was performed using log-rank test. The 95% confidence
intervals for the survival analysis were calculated by beta pro-
duct confidence procedure (BPCP), that is, a non-parametric
confidence procedure method designed specifically for small
sample size [14]. A p-value <0.05 was considered significant,
while a p-value of 0.05–0.1 considered borderline statistical
significance.Results
This study included 77 patients who were diagnosed and trea-
ted as LBL during the period from July 2007 [date of inaugu-
ration of the hospital] to end of December 2012, representing
14.6% of the total number of patient (525) diagnosed with
NHL during the same period. The median age at diagnosis
was 9 years (range 1–17 years) with 95% confidence interval
(95% CI: 7–10). They were 54 males (70.1%) and 23 females
(29.8%).
The most common presentation was mediastinal mass
seen in 40 patients (51.9%), and respiratory distress in 26
(33.7%), followed by generalized lymph nodes enlargement
in 22 (28.5%), and cervical lymphadenopathy in 5 (6.4%)
of the patients. T-cell LBL patients were 67 patients
(87%), while 10 were B-cell (13%). Stage III was the most
common at presentation seen in 51 patients (66.2%),
Figure 2 Event free survival of all the studied patients.
Table 2 Causes of death among the studied patients.
Total 12 Percentage (95% CI)
Early 2
Septicemia (CR) 2
Relapse/PD 8 66.67 (34.89–90.08)
Table 3 Site and timing of relapsed patients.
Patients Site Timing Cause of death
1. CNS &
local
Maintenance
week 44
Septicemia during
chemotherapy
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(16.8%). Two patients (2.59%) had stage I disease. BM
infiltration (<25%) was detected in 11 (14.3%), while
CNS infiltration was detected in 2 of the patients
(2.59%). Table 1 describes the clinical characteristics of
the studied patients.
Chemotherapy response
Two patients were excluded from analysis as they died before
receiving chemotherapy. Following induction chemotherapy,
complete remission (CR) was detected in 20/75 patients (early
responders, 26.7%), and partial remission in 55/75 patients
(late responders, 73.3%). By the end of the consolidation
phase (day 100), 66/75 patients were in CR, while 9/75 still
had residual tumor. The median of the duration of follow up
was 47 months (range 1–89 months) (95% CI: 38–56). The
4 year overall survival (OS) and event free survival (EFS) were
86.45% (95% CI: 73.78–94.09) and 82.18% (95% CI: 69.25–
90.61) respectively (Figs. 1 and 2). Other parameters were
tested with uni-variant analysis including age, sex, localized
(stages I & II) versus advanced disease (stages III & IV) and
were statistically insignificant.
Causes of death, relapses, and disease progression
Twelve patients died during the study period; 2 early deaths
before starting chemotherapy from disease progression, 2
while in CR due to chemotherapy related toxicity, while 8 from
disease progression (Table 2).
Seven patients relapsed, while 1 had PD during consolida-
tion phase. They all had advanced disease at presentation
(6 with stage III; 2 with stage IV), and had T-cell IPT. Two
patients had isolated local, BM, and CNS relapse each, while
1 had both local and CNS relapse. Disease recurrence was
local in 3 patients, and systemic in 5, while it was early in 6,
and late in 2 patients. All relapsed patients did not surviveFigure 1 Overall survival of all the studied patients.
2. BM Maintenance
week 48
Chemotherapy toxicity
3. CNS During FU PD on chemotherapy
4. CNS Maintenance
[week 41]
PD on chemotherapy
5. Local
[Chest]
Consolidation
phase
Septicemia during
chemotherapy
6. BM Maintenance
[week 44]
PD post Allogeneic
HSCT
7. BM Maintenance
[week 13]
PD on chemotherapy
8. Local
[nodal]
During FU PD on chemotherapysalvage chemotherapy. Table 3 describes causes of death,
and timing of in relation to chemotherapy.Chemotherapy toxicities
The most common chemotherapy toxicities were cerebral
venous thrombosis (21%), followed by bone infarcts
(10.6%), and avascular necrosis of head of femur (9.3%).
One patient developed secondary AML after 3 years of FU
with unfavorable cytogenetic aberrations (Table 3).
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This report presents the results of a retrospective study includ-
ing LBL patients treated according to ALL Total Therapy
Study XV at St. Jude Children’s Research Hospital during
5.5 years. The mean age at diagnosis was 9 years which is sim-
ilar to other reports [4,15,17,18], while other reports showed a
younger mean age ranging from 7 to 8 years [10,18–20]. The
male predominance present in the current study is well docu-
mented in most similar studies [4,16,19,21] (see Table 4).
In our study, mediastinal mass, T-cell LBL, and stage III
Murphy’s classification were the most common modes of pre-
sentation. This observation was made as well by many authors
[10,15,17,18]. B-cell LBL in our study represented 10% of the
cohort, similar to other studies; 14.8% [18], 12.2% [21], 23%
[17]. In B-cell LBL, bone, skin and SC nodules were a common
mode of presentation, and early stages represented 75% of the
patients [20].
In the current study, BM infiltration was detected in 14.3%,
similar to other study groups as 10.8% [15], 14.2% [4], rising
up to 22% [16], 27% [17], and as high as 42.6% [18], 44% in
adult patients [22]. Central nervous system (CNS) infiltration
was detected in 2.6% of our patients. Data in the literature
are heterogeneous with a rate of infiltration ranging from
0.7% up to 15% in adults [15,17,18,21,22]. In most of the stud-
ies, including the present one, BM and/or CNS infiltration
were not recognized as an independent prognostic factor for
OS and EFS [23,24]. In contrast, Jabbour et al. (2006) defined
BM infiltration as a strong prognostic factor in adults [22].
Following induction chemotherapy, CR was detected in
26.7% of the patients, PR in 73.3%, while at day 100, 88%
where in CR and 12% still had residual tumor. Similar CR rate
was reported by many other groups as 70% [15], 77.8% [18],
95% [21], 63% [4], 57% [17], and 75%, 67% [19,22]. Higher
CR rates were reported in EORTC trials 58881 as 92.3%,
95% [16,20], with different definitions of time of response
[16,17,19–21] making data comparison more difficult.
Evaluation of residual mass was one of the major
difficulties during the treatment [25]. The lack of reliable
biological and/or radiological prognostic factors rendered
the decision making in continuing treatment despite the
presence of residual tumor a controversial one. Moreover,Table 4 Chemotherapy toxicity encountered during chemotherapy.
Organ Percentage (95% CI)
Total number (n= 59)
Cardiac 4
Chest 3
Pancreas 1
Cerebrovascular 21 35.59% (23.55–
49.13)
Thrombosis
PRESS
Infarcts
Bone 29 49.15% (35.89–62.5)
AVN
Osteopenia & infarcts
Pathologic fracture
Therapy related AML 1
AML: Acute Myeloid Leukemia, AVN: Avascular necrosis, PRESS: Pospathologic documentation especially in high risk organs poses
many problems, and holds unnecessary risks. In the current
study, patients continued treatment despite the presence of
radiologically documented residual mass till the evidence proof
of progressive disease. The prognostic relevance of residual
mediastinal infiltration in patients with bulky disease at pre-
sentation didn’t seem to influence a long term outcome in
childhood LBL [26].
OS for early versus late responders was statistically signifi-
cant as 100% and 81.7% respectively (p-value = 0.04). Other
parameters including age, sex, T versus B cell, stage I/II versus
III/IV were tested in univariate analysis and had no statistical
significance. Data concerning the presence of prognostic fac-
tors are controversial. Uytterbroeck et al. (2008) reported
100% OS for 13% of patients with T-cell LBL in CR after
7 days of steroids and IT Methotrexate, and concluded that
CR at day 7 of steroid therapy carries a good prognosis [16],
while Ducassou et al. (2010) concluded that disease stage
(stage I-III, versus stage IV) has a major prognostic factor with
better OS and EFS [16]. In the NHL-BFM-95 protocol, treat-
ment was adjusted according to initial stage, and response at
day 33 induction chemotherapy [4]. Pillon et al. reported in
2015 that there was no statistically significant difference in
DFS observed between patients who obtained early or late
CR. Moreover, no subgroup or prognostic factors could be
identified [17].
The median of the duration of follow up 47 months (range
1–89 months). The 4 years OS, EFS were 86.45% and 82.18%
respectively. Our results are similar to most of those reported
in the literature as OS 86.5% [15], lower than results reported
by Sandlund (2009) as 5 years OS 90.2% and EFS 82.9% [21].
Reiter et al. for the BFM group reported 5 years EFS as 90%
[4], and much better than the Chinese result reported by Gao et
el (2014) as EFS 63.9% [18], and 63% [22]. Pillon et al.
reported a 7 year OS 82%, EFS 74% [17].
In the current study, 10.4% of patient relapsed or had dis-
ease progression. They were all T-cell, and had an advanced
stage. Our relapse rate is similar to what is reported in the lit-
erature as 13.5% [15],7.3% [21], 11% for T cell and 8% for B
cell LBL [27], 16% [16], and much lower than Gao et al. (2014)
as 23.1% [18], 22% [17]. Temuhlen et al. (2012) reported 8.9%
relapse rate in localized LBL treated on COG trial A5971 [19],Grade
Grade 1–2 (mild) Grade 3–4 (moderate) Grade 5 (sever; death)
– 2 2
3 – –
1 – –
1 15 –
– 2 –
– 3 –
– 11 –
– 14 –
4 – –
terior Reversible Leukoencephalopathy syndrome.
180 H.A. Rahman Sayed et al.while Jabbour et al. reported 52% relapse rate in T cell LBL in
adults [22]. As we can see from previous data, relapse rate is
constant irrespective of disease stage [19], B [20,27], or T cell
[22,27], with very few identifiable prognostic factors [18,19].
All relapsed patients in the current study died either from
toxicity of salvage chemotherapy, or tumor progression,
including one patient following allogeneic HSCT. Survival in
relapsed patients is dismal. Burkhardt et al reported about
the extremely poor outcome of patients who fail 1st line
chemotherapy [27]. Following salvage chemotherapy and allo-
geneic HSCT transplant, OS for relapsed patients ranged from
7.4% [4] to 14% [27]. Ducassou et al. (2011) had 15.1% relapse
rate in B-cell LBL, and they all died [20]. Moreover, difficulty
in salvage therapy of relapsed patients has been mentioned by
many study groups [20,27]. Duration of chemotherapy for
LBL patients remains controversial. Patients in our study
received induction, consolidation followed by a 24 months
maintenance chemotherapy. Many centers treat low stage for
a shorter duration [28], or lower dose of chemotherapy
[4,28], but the average duration of therapy remains 24 months.
One patient developed secondary AML after 3 years of FU,
refusing salvage chemotherapy, and is under palliative treat-
ment. Similarly, secondary malignancy was reported in many
studies with various rates of incidence, mainly AML
[4,17,19,21]. Other reported secondary malignancy included
cancer thyroid [17], pelvic Ewing’s sarcoma [19], melanoma
and stage IV glioblastoma [20].
In the current study, osteopenia, bony infarcts and avascu-
lar necrosis (ANV) of head of femur were the most common
long term side effects of chemotherapy. Relling et al. (2004)
reported that 26% of the patients had asymptomatic MRI
changes at week 10 of maintenance chemotherapy, with minor-
ity of them requiring surgical intervention [29]. Risk factors for
developing osteonecrosis were age between 16 and 20, females,
obesity [30], and the association of dexamethasone and aspar-
ginase commonly used in the total XV protocol [31]. In the
ALL BFM 95, the 5-year cumulative incidence of symptomatic
osteonecrosis was 1.8% with more predominance in those
above 10 years of age and particularly adolescents >15 years
[32]. In a recent study about the impact of Dexamethasone ver-
sus prednisolone, on the incidence of osteonecrosis, it proved
that it was similar in both arms. On the other hand, vincristine
steroid pulses during maintenance treatment were responsible
of more osteonecrosis 4.4% versus 2% [33].
Steroid therapy was reduced to 6 mg/m2 or stopped once
the radiologic bony changes were detected.
Other commonly detected toxicity was cerebrovascular
thrombosis, seen in 27.2% of the patients, a common toxicity
of the association of dexamethasone and asparginase, man-
aged symptomatically with no serious complications. The toxic
effect of pegylated asparginase in the form of adverse events,
infections and hospitalization was lesser or similar to the
native E. Coli form with sometimes a higher rate of pancreati-
tis [34]. In an experience on compassionate basis, using pegy-
lated asparginase in multi relapsed and refractory ALL, the
toxicity was severe allergic manifestations, however rapidly
responding to treatment with no CNS thrombotic event or
acute pancreatitis [35]. In a recent 5 year prospective multicen-
ter cohort study the Nordic Society of Paediatric Haematology
and Oncology ALL 2008 protocol, 20 children out of 1038,
presented with cerebral sinus venous thrombosis with a cumu-
lative incidence of 2%. Sixteen of the thromboses were relatedto asparginase, and 16 to steroids. Most accidents occurred in
the consolidation phase [36]. In our center, pegylated aspargi-
nase is not available.Conclusion
Results of treatment of LBL on the St Jude’s total therapy XV
study are comparable to most of the reported studies. Out-
come of relapsing patients is extremely poor, hence the need
to identify biologic or clinical prognostic factors including
minimal residual tumor to better evaluate chemotherapy
response. Steroids induced AVN, and cerebral vascular throm-
bosis was the main chemotherapeutic adverse events.
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